Industry News
Virtual Vision Health Launches Visual Acuity Testing on Virtual Eye VR Platform

Virtual Vision Health has announced the launch of visual acuity testing on its innovative Virtual Ey...

read more
Virtual Vision Health Launches Visual Acuity Testing on Virtual Eye VR Platform
February 13, 2025
OKYO Pharma’s Lead Asset OK-101 Receives US Adopted Name “urcosimod”

OKYO Pharma has announced that its lead investigational asset, OK-101, has been officially assigned ...

read more
OKYO Pharma’s Lead Asset OK-101 Receives US Adopted Name “urcosimod”
February 13, 2025
EssilorLuxottica Acquires Cellview Imaging to Strengthen Retinal Diagnostic Capabilities

EssilorLuxottica has announced the acquisition of Cellview Imaging, a Toronto-based med-tech start-u...

read more
EssilorLuxottica Acquires Cellview Imaging to Strengthen Retinal Diagnostic Capabilities
February 12, 2025
TECLens Secures $9.3 Million in Series A Funding to Advance Noninvasive Refractive Technology

TECLens has successfully raised $9.3 million in Series A funding to accelerate the clinical developm...

read more
TECLens Secures $9.3 Million in Series A Funding to Advance Noninvasive Refractive Technology
February 12, 2025
AEYE Health and Topcon Healthcare Announce Results of Autonomous Diabetic Retinopathy Screening Study

AEYE Health and Topcon Healthcare have unveiled promising results from a recent study evaluating Top...

read more
AEYE Health and Topcon Healthcare Announce Results of Autonomous Diabetic Retinopathy Screening Study
February 12, 2025
Clearside Biomedical Presents New Data from ODYSSEY Phase 2b Trial on CLS-AX

Clearside Biomedical has shared new insights from two subgroup analyses of its ODYSSEY Phase 2b clin...

read more
Clearside Biomedical Presents New Data from ODYSSEY Phase 2b Trial on CLS-AX
February 11, 2025
Bausch + Lomb Provides Update on Potential Sale and Future Plans

Bausch + Lomb has announced that it has no immediate plans to go private, following an evaluation of...

read more
Bausch + Lomb Provides Update on Potential Sale and Future Plans
February 11, 2025
Regeneron Reports Positive Phase 3 Trial Results for EYLEA HD (Aflibercept) 8 mg

Regeneron Pharmaceuticals has announced promising results from two major clinical trials—the Phase 3...

read more
Regeneron Reports Positive Phase 3 Trial Results for EYLEA HD (Aflibercept) 8 mg
February 11, 2025
Pykus Therapeutics to Present Initial Clinical Data on Novel Retinal Sealant PYK-2101

Pykus Therapeutics has announced it will present initial clinical data on PYK-2101, an investigation...

read more
Pykus Therapeutics to Present Initial Clinical Data on Novel Retinal Sealant PYK-2101
February 07, 2025
Lumenis Launches OptiLIFT to Address Lower Lid Laxity and Impaired Blinking

Lumenis Be. Ltd., a global leader in energy-based medical devices for eye care and aesthetics, has a...

read more
Lumenis Launches OptiLIFT to Address Lower Lid Laxity and Impaired Blinking
February 07, 2025
More